ABNX — Abionyx Pharma SA Share News
0.000.00%
Last trade - 00:00- €62.99m
- €51.30m
- €4.06m
Brief: Abionyx Pharma Completes A Capital Increase Of Around EUR 3 Mln
Brief: Abionyx H1 Operating Loss Narrows To EUR 2.2 Mln
Brief: Abionyx Pharma Announces H1 Sales Of EUR 2.1 Mln
Brief: Abionyx Pharma Successfully Manufactures Second Batch For GMP Industrial Biomanufacturing of CER-001
Brief: Abionyx Pharma Announces Unanimous Approval Of All Resolutions Put To Vote At Its Combined General Meeting
Brief: Abionyx Pharma Provides Further Details On The Setting Up Of Its Equity-Linked Financing Facility
Brief: ABIONYX Pharma Announces Subscription Of Equity-Linked Facility With IRIS
Brief: Abionyx Pharma: Cash Position Of EUR 2.9 Million As Of March 31
Brief: Abionyx Pharma FY Net Loss Narrows To EUR 4.2 Million
Brief: Abionyx Pharma Reports Positive Results From Phase 2A Trial Of Cer-001 For Septic Patients At High Risk Of AKI
Brief: Abionyx Pharma End-Sept Cash Position Of 3.8 Million Euros
Brief: Abionyx Announces Recruitment Of Last Patient In Phase 2A Clinical Trial With CER-001
French and Benelux stocks-Factors to watch
Brief: Abionyx Pharma H1 Revenue Up At 2.5 Millon Euros
Brief: Abionyx Pharma: Cash Position of EUR 4.0 Mln As Of June 30
Brief: Abionyx Pharma End-March Cash Position Of EUR 5.9 Million
Brief: Abionyx Pharma End-Dec Operating Loss Widens To 5.9 Million Euros
Abionyx jumps on positive trial results in therapy for septic patients
Brief: Abionyx Pharma Reports Positive Interim Results From Phase 2a Trial Of CER-001 For Septic Patients At High Risk Of AKI